Qiagen (NYSE:QGEN) Shares Acquired by Atria Investments Inc

Atria Investments Inc boosted its position in Qiagen (NYSE:QGEN) by 6.0% in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 7,632 shares of the company’s stock after purchasing an additional 433 shares during the quarter. Atria Investments Inc’s holdings in Qiagen were worth $348,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in QGEN. Victory Capital Management Inc. lifted its stake in shares of Qiagen by 104,759.6% during the second quarter. Victory Capital Management Inc. now owns 1,583,380 shares of the company’s stock valued at $65,061,000 after buying an additional 1,581,870 shares during the period. Earnest Partners LLC raised its holdings in Qiagen by 85.1% in the 1st quarter. Earnest Partners LLC now owns 3,427,605 shares of the company’s stock valued at $147,353,000 after acquiring an additional 1,576,259 shares during the last quarter. Nuance Investments LLC lifted its stake in shares of Qiagen by 17.3% during the 2nd quarter. Nuance Investments LLC now owns 5,271,494 shares of the company’s stock worth $216,606,000 after purchasing an additional 778,005 shares during the period. Point72 Asset Management L.P. boosted its holdings in shares of Qiagen by 148.8% during the second quarter. Point72 Asset Management L.P. now owns 1,184,806 shares of the company’s stock worth $48,684,000 after purchasing an additional 708,533 shares during the last quarter. Finally, DekaBank Deutsche Girozentrale grew its position in shares of Qiagen by 12.2% in the second quarter. DekaBank Deutsche Girozentrale now owns 3,248,354 shares of the company’s stock valued at $133,292,000 after purchasing an additional 353,280 shares during the period. 70.00% of the stock is currently owned by hedge funds and other institutional investors.

Qiagen Stock Up 0.6 %

QGEN opened at $42.33 on Friday. Qiagen has a 1 year low of $39.03 and a 1 year high of $47.44. The firm has a 50 day moving average price of $43.57 and a 200 day moving average price of $43.73. The company has a debt-to-equity ratio of 0.39, a quick ratio of 1.89 and a current ratio of 2.17. The company has a market cap of $9.66 billion, a PE ratio of 108.38, a price-to-earnings-growth ratio of 3.16 and a beta of 0.41.

Wall Street Analysts Forecast Growth

Several research firms recently weighed in on QGEN. Robert W. Baird increased their target price on Qiagen from $49.00 to $52.00 and gave the stock an “outperform” rating in a research report on Friday, August 2nd. Hsbc Global Res upgraded shares of Qiagen to a “hold” rating in a report on Thursday, October 17th. Finally, HSBC downgraded shares of Qiagen from a “buy” rating to a “hold” rating and set a $49.00 target price for the company. in a report on Thursday, October 17th. Four investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $50.88.

About Qiagen

QIAGEN N.V. offers sample to insight solutions that transform biological materials into molecular insights worldwide. The company provides primary sample technology consumables, such as nucleic stabilization and purification kits for primary sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids from secondary sample materials; and instruments for nucleic acid purification and accessories.